{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:03:54Z","timestamp":1770041034883,"version":"3.49.0"},"reference-count":56,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"construction project of the medical technology research and development plan of Henan province in 2021","award":["LHGJ20210135"],"award-info":[{"award-number":["LHGJ20210135"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Protein-based pneumococcal vaccines (PBPVs) may offer expanded protection against Streptococcus pneumoniae and tackle the antimicrobial resistance crisis in pneumococcal infections. This study examined the safety and immunogenicity in healthy adults vaccinated with three doses of a protein-based pneumococcal vaccine containing pneumococcal surface protein A (PspA) (PRX1, P3296 and P5668) and in combination with a recombinant detoxified pneumolysin protein (PlyLD). Methods: This phase Ia randomized, double blind, placebo-controlled clinical study enrolled healthy adults aged 18\u201349 years. The participants were randomized into experimental (low-dose, medium-dose, high-dose) and placebo groups in a ratio of 3:1. Three doses of investigational vaccine were given to the participants with an interval of two months. Safety endpoints included the occurrence of total adverse reactions, solicited local and systemic adverse reactions, unsolicited adverse reactions, serious adverse events (SAEs), and several laboratory parameters. Immunogenicity endpoints included geometric mean titers (GMT) of anti-PspA (PRX1, P3296 and P5668) and anti-PlyLD antibodies level as determined by ELISA, seropositivity rates of PspA and PlyLD antibodies (&gt;4-fold increase) and neutralization activity of anti-Ply antibody in serum. Results: A total of 118 participants completed the study of three doses. The candidate PBPV was safe and well-tolerated in all experimental groups. No vaccine-related SAEs were observed in this study. Most solicited adverse reactions were mild and transient. The most frequently reported solicited adverse reactions in the medium- and high-dose groups was pain at the injection site, while in the low-dose group it was elevated blood pressure. The immunogenicity data showed a sharp increase in the GMT level of anti-PspA-RX1, anti-PspA-3296, anti-PspA-5668, and anti-PlyLD antibodies in serum. The results also showed that the elicited antibodies were dosage-dependent. The high-dose group showed a higher immune response against PspA-RX1, PspA-3296, PspA-5668, and PlyLD antigens. However, repeat vaccination did not increase the level of anti-PspA antibodies but the level of anti-PlyLD antibody. High seropositivity rates were also observed for anti-PspA-RX1, anti-PspA-3296, anti-PspA-5668, and anti-PlyLD antibodies. In addition, a significant difference in the GMT levels of anti-Ply antibody between the high-, medium-, and low-dose groups post each vaccination were indicated by neutralization activity tests. Conclusions: The PBPV showed a safe and immunogenic profile in this clinical trial. Taking into consideration both safety and immunogenicity data, we propose a single dose of 50 \u00b5g (medium dose) of PBPV as the optimum approach in providing expanded protection against Streptococcus pneumoniae.<\/jats:p>","DOI":"10.3390\/vaccines12080827","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T11:40:36Z","timestamp":1721734836000},"page":"827","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18\u201349: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Yanxia","family":"Wang","sequence":"first","affiliation":[{"name":"Henan Center for Disease Control and Prevention, Zhengzhou 450016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Shi","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing 100050, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Xie","sequence":"additional","affiliation":[{"name":"Henan Center for Disease Control and Prevention, Zhengzhou 450016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbo","family":"Gou","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Huang","sequence":"additional","affiliation":[{"name":"Henan Center for Disease Control and Prevention, Zhengzhou 450016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Huang","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangyang","family":"You","sequence":"additional","affiliation":[{"name":"Henan Center for Disease Control and Prevention, Zhengzhou 450016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijie","family":"Wang","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongli","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Health Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyu","family":"Wang","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[{"name":"CanSino Biologics Inc., Tianjin 300457, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Henan Center for Disease Control and Prevention, Zhengzhou 450016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41579-018-0001-8","article-title":"Streptococcus pneumoniae: Transmission, colonization and invasion","volume":"16","author":"Weiser","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Morimura, A., Hamaguchi, S., Akeda, Y., and Tomono, K. (2021). Mechanisms Underlying Pneumococcal Transmission and Factors Influencing Host-Pneumococcus Interaction: A Review. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.639450"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ganaie, F., Maruhn, K., Li, C., Porambo, R.J., Elverdal, P.L., Abeygunwardana, C., van der Linden, M., Duus, J., Sheppard, C.L., and Nahm, M.H. (2021). Structural, Genetic, and Serological Elucidation of Streptococcus pneumoniae Serogroup 24 Serotypes: Discovery of a New Serotype, 24C, with a Variable Capsule Structure. J. Clin. Microbiol., 59.","DOI":"10.1128\/JCM.00540-21"},{"key":"ref_4","unstructured":"World Health Organization (2023, November 01). WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. Available online: https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kim, S.H., Bae, I.K., Park, D., Lee, K., Kim, N.Y., Song, S.A., Kim, H.R., Jeon, G.W., Urm, S.-H., and Shin, J.H. (2016). Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Isolates Causing Invasive and Noninvasive Pneumococcal Diseases in Korea from 2008 to 2014. BioMed Res. Int., 2016.","DOI":"10.1155\/2016\/6950482"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00309","DOI":"10.1128\/mBio.00309-10","article-title":"Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States","volume":"2","author":"Simonsen","year":"2011","journal-title":"mBio"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1473-3099(17)30049-X","article-title":"Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: A multicentre, prospective, test-negative design study","volume":"17","author":"Suzuki","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Subramanian, K., Henriques-Normark, B., and Normark, S. (2019). Emerging concepts in the pathogenesis of the Streptococcus pneumoniae: From nasopharyngeal colonizer to intracellular pathogen. Cell. Microbiol., 21.","DOI":"10.1111\/cmi.13077"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Scott, N.R., Mann, B., Tuomanen, E.I., and Orihuela, C.J. (2021). Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9030209"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.coi.2011.03.004","article-title":"T cell-independent B cell memory","volume":"23","author":"Defrance","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Balsells, E., Guillot, L., Nair, H., and Kyaw, M.H. (2017). Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0177113"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Masomian, M., Ahmad, Z., Gew, L.T., and Poh, C.L. (2020). Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection. Vaccines, 8.","DOI":"10.3390\/vaccines8010132"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2017.10.076","article-title":"Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial","volume":"35","author":"Entwisle","year":"2017","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1016\/j.vaccine.2015.06.078","article-title":"Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study","volume":"33","author":"Brooks","year":"2015","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/21645515.2015.1111496","article-title":"Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2\u20134 years: A phase II randomized study","volume":"12","author":"Odutola","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6838","DOI":"10.1016\/j.vaccine.2014.02.052","article-title":"Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I\/II randomized clinical study","volume":"32","author":"Maes","year":"2014","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.vaccine.2017.03.071","article-title":"Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study","volume":"35","author":"Odutola","year":"2017","journal-title":"Vaccine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1128\/IAI.00378-10","article-title":"Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens","volume":"79","author":"Godfroid","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1016\/j.vaccine.2012.10.080","article-title":"Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults","volume":"30","author":"Seiberling","year":"2012","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/14760584.2017.1393335","article-title":"Pneumococcal whole-cell and protein-based vaccines: Changing the paradigm","volume":"16","author":"Pichichero","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14712598.2018.1384462","article-title":"Development of pneumococcal vaccines over the last 10 years","volume":"18","author":"Principi","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10-1128","DOI":"10.1128\/microbiolspec.GPP3-0028-2018","article-title":"Pneumococcal Vaccines","volume":"7","author":"Briles","year":"2019","journal-title":"Microbiol Spectr."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lagousi, T., Basdeki, P., Routsias, J., and Spoulou, V. (2019). Novel Protein-Based Pneumococcal Vaccines: Assessing the Use of Distinct Protein Fragments Instead of Full-Length Proteins as Vaccine Antigens. Vaccines, 7.","DOI":"10.3390\/vaccines7010009"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1128\/IAI.72.5.2689-2697.2004","article-title":"CD4-T-Lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection","volume":"72","author":"Kadioglu","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1073\/pnas.0435928100","article-title":"Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection","volume":"100","author":"Malley","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1016\/j.vaccine.2018.05.122","article-title":"Immunogenicity and mechanisms of action of PnuBioVax, a multi-antigen serotype-independent prophylactic vaccine against infection with Streptococcus pneumoniae","volume":"36","author":"Hill","year":"2018","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1128\/IAI.68.2.796-800.2000","article-title":"Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae","volume":"68","author":"Briles","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1128\/CVI.00430-09","article-title":"Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection","volume":"17","author":"Moreno","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Oliveira, M.L.S., Miyaji, E.N., Ferreira, D.M., Moreno, A.T., Ferreira, P.C.D., Lima, F.A., Santos, F.L., Sakauchi, M.A., Takata, C.S., and Higashi, H.G. (2010). Combination of pneumococcal surface protein A (PspA) with Whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010863"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1128\/IAI.00240-13","article-title":"Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae","volume":"81","author":"Kong","year":"2013","journal-title":"Infect. Immun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"E91","DOI":"10.1002\/lary.26971","article-title":"Transcutaneous immunization with pneumococcal surface protein A in mice","volume":"128","author":"Nagano","year":"2018","journal-title":"Laryngoscope"},{"key":"ref_32","unstructured":"National Medical Products Administration (2024, July 01). Good Manufacturing Practice for Drugs, Available online: https:\/\/english.nmpa.gov.cn\/2019-07\/25\/c_390613.htm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1128\/IAI.68.10.5889-5900.2000","article-title":"Diversity of PspA: Mosaic genes and evidence for past recombination in Streptococcus pneumoniae","volume":"68","author":"Hollingshead","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.1016\/j.vaccine.2018.08.045","article-title":"The diversity of the proline-rich domain of pneumococcal surface protein A (PspA): Potential relevance to a broad-spectrum vaccine","volume":"36","author":"Mukerji","year":"2018","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3201\/eid0705.017510","article-title":"Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from Colombian children","volume":"7","author":"Fonseca","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1016\/j.vaccine.2004.04.009","article-title":"Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: Towards novel pneumococcal protein vaccines","volume":"22","author":"Brandileone","year":"2004","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1365-2249.2006.03148.x","article-title":"Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults","volume":"145","author":"Baril","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Akbari, E., Negahdari, B., Faraji, F., Behdani, M., Kazemi-Lomedasht, F., and Habibi-Anbouhi, M. (2019). Protective responses of an engineered PspA recombinant antigen against Streptococcus pneumoniae. Biotechnol. Rep., 24.","DOI":"10.1016\/j.btre.2019.e00385"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1128\/IAI.73.3.1304-1312.2005","article-title":"Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae","volume":"73","author":"Gor","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0264-410X(99)00530-7","article-title":"Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules","volume":"18","author":"Nabors","year":"2000","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1016\/j.vaccine.2012.10.076","article-title":"Safety and immunogenicity of pneumococcal protein vaccine candidates: Monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA\u2013pneumococcal histidine triad protein D vaccine","volume":"30","author":"Bologa","year":"2012","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.vaccine.2012.11.005","article-title":"Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults","volume":"31","author":"Kamtchoua","year":"2013","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1128\/iai.58.10.3293-3299.1990","article-title":"Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae","volume":"58","author":"Crain","year":"1990","journal-title":"Infect Immun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1128\/iai.59.1.222-228.1991","article-title":"PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type","volume":"59","author":"McDaniel","year":"1991","journal-title":"Infect. Immun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s10156-008-0647-7","article-title":"Protection against systemic fatal pneumococcal infection by maternal intranasal immunization with pneumococcal surface protein A (PspA)","volume":"14","author":"Katsurahara","year":"2008","journal-title":"J. Infect. Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1128\/CVI.00395-08","article-title":"Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice","volume":"16","author":"Ferreira","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1016\/j.vaccine.2012.09.015","article-title":"Effective protection against secondary pneumococcal pneumonia by oral vaccination with attenuated Salmonella delivering PspA antigen in mice","volume":"30","author":"Seo","year":"2012","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"McNeela, E.A., Burke, \u00c1., Neill, D.R., Baxter, C., Fernandes, V.E., Ferreira, D., Smeaton, S., El-Rachkidy, R., McLoughlin, R.M., and Mori, A. (2010). Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001191"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Morais, V., Texeira, E., and Suarez, N. (2019). Next-Generation Whole-Cell Pneumococcal Vaccine. Vaccines, 7.","DOI":"10.3390\/vaccines7040151"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1128\/iai.62.12.5683-5688.1994","article-title":"Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae","volume":"62","author":"Alexander","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1128\/IAI.69.10.5997-6003.2001","article-title":"Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA","volume":"69","author":"Ogunniyi","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/IAI.72.8.4534-4540.2004","article-title":"Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin","volume":"72","author":"Garci","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1016\/j.vaccine.2011.05.051","article-title":"A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae","volume":"29","author":"Philipp","year":"2011","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1128\/CVI.00430-13","article-title":"Safety, Immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults","volume":"21","author":"Berglund","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7482","DOI":"10.1016\/j.vaccine.2019.09.076","article-title":"Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study","volume":"37","author":"Hammitt","year":"2019","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Nishimoto, A.T., Rosch, J.W., and Tuomanen, E.I. (2020). Pneumolysin: Pathogenesis and Therapeutic Target. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.01543"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/8\/827\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:21:28Z","timestamp":1760109688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/8\/827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["vaccines12080827"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12080827","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}